9 years ago

ApcinteX Secures £14m Series A Funding for Haemophilia Treatment

  • ApcinteX, a University of Cambridge spin-out developing a new treatment for haemophilia, raised £14 million in Series A funding

  • The round was co-led by Medicxi and Touchstone Innovations Group plc, with participation from Cambridge Enterprise

  • The company's treatment seeks to reduce the activity of a key natural anticoagulant pathway to achieve normal blood clotting in haemophilia patients.

      • ProblemLife Sciences

      "making a new treatment for haemophilia that can produce normal blood clotting in patients with severe bleeding disorders"

      Solution

      "developing a therapy that turns down the activity of a key natural anticoagulant pathway to enable normal blood clotting"

      Covered on